Regeneron
Develops antibody and genetic medicines led by Dupixent, EYLEA HD, and Libtayo.
$793.21
After-hours close−0.89 (−0.11%)
At close$794.10(−1.69%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $16.00 | — | — |
| Jul 2026 | $10.16 | $14.29 | +40.6% |
| Apr 2026 | $8.91 | $9.47 | +6.3% |
| Jan 2026 | $10.74 | $11.44 | +6.5% |
| Oct 2025 | $9.65 | $11.83 | +22.6% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 28, 2026 | $16.00 | — | — | $4.54B | — | — |
| Jul 30, 2026 | $10.16 | $14.29 | +40.6% | $3.82B | $4.29B | +12.4% |
| Apr 29, 2026 | $8.91 | $9.47 | +6.3% | $3.48B | $3.61B | +3.6% |
| Jan 30, 2026 | $10.74 | $11.44 | +6.5% | $3.81B | $3.88B | +1.9% |
| Oct 28, 2025 | $9.65 | $11.83 | +22.6% | $3.59B | $3.75B | +4.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 1, 2025 | ||||||
| Apr 29, 2025 | ||||||
| Feb 4, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Aug 1, 2024 | ||||||
| May 2, 2024 | ||||||
| Feb 2, 2024 | ||||||
| Nov 2, 2023 | ||||||
| Aug 3, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 3, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 3, 2022 | ||||||
| May 4, 2022 | ||||||
| Feb 4, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Feb 5, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 5, 2020 | ||||||
| May 5, 2020 | ||||||
| Feb 6, 2020 | ||||||
| Nov 5, 2019 | ||||||
| Aug 6, 2019 | ||||||
| May 7, 2019 | ||||||
| Feb 6, 2019 | ||||||
| Nov 6, 2018 | ||||||
| Aug 2, 2018 | ||||||
| May 3, 2018 | ||||||
| Feb 8, 2018 | ||||||
| Nov 8, 2017 | ||||||
| Aug 3, 2017 | ||||||
| May 4, 2017 | ||||||
| Feb 9, 2017 | ||||||
| Nov 4, 2016 | ||||||
| Aug 4, 2016 | ||||||
| May 5, 2016 | ||||||
| Feb 9, 2016 | ||||||
| Nov 4, 2015 | ||||||
| Aug 4, 2015 | ||||||